2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow CC-90001: new trials by email Literature Review of CC-90001 trials Research Report on CC-90001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis CC-90001, Placebo - Non-alcoholic Fatty Liver Disease, Liver Cirrhosis | Phase 2 | Terminated | Celgene | 56 | 2019-08-14 | 2023-06-07 |
| A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis CC-90001, Placebo - Idiopathic Pulmonary Fibrosis, Fibrosis | Phase 2 | Terminated | Celgene | 138 | 2017-07-26 | 2023-06-28 |
Fibrosis (1) · Idiopathic Interstitial Pneumonias (1) · Idiopathic Pulmonary Fibrosis (1) · Liver Cirrhosis (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Non-alcoholic Fatty Liver Disease (1) · Pathologic Processes (1) · Pulmonary Fibrosis (1) · Respiratory Tract Diseases (1)
Celgene (2)
Australia (2) · Canada (2) · Germany (2) · United Kingdom (2) · United States (2) · Brazil (1) · Colombia (1) · France (1) · Greece (1) · Japan (1) · Poland (1) · Romania (1) · Russia (1) · South Korea (1) · Spain (1)
PMID 34894681, PMID 35058236, PMID 38484130
2016 (1), 2018 (1)